SG Americas Securities LLC Buys 24,102 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

SG Americas Securities LLC raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 276.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,812 shares of the biopharmaceutical company's stock after acquiring an additional 24,102 shares during the quarter. SG Americas Securities LLC's holdings in Catalyst Pharmaceuticals were worth $685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Dakota Wealth Management purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $236,000. Redhawk Wealth Advisors Inc. purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth $1,273,000. Richard P Slaughter Associates Inc increased its position in shares of Catalyst Pharmaceuticals by 1.9% during the 4th quarter. Richard P Slaughter Associates Inc now owns 149,406 shares of the biopharmaceutical company's stock valued at $3,118,000 after purchasing an additional 2,770 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter worth approximately $134,000. Finally, Oliver Luxxe Assets LLC grew its position in Catalyst Pharmaceuticals by 103.5% during the fourth quarter. Oliver Luxxe Assets LLC now owns 69,250 shares of the biopharmaceutical company's stock valued at $1,445,000 after acquiring an additional 35,225 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Price Performance

CPRX stock traded up $0.01 during trading on Monday, hitting $22.57. 823,464 shares of the stock traded hands, compared to its average volume of 1,442,473. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 19.20, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.12 and a 1 year high of $24.64. The firm's 50 day moving average is $21.98 and its two-hundred day moving average is $20.75.

Insider Activity

In other news, insider Steve Miller sold 50,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Molly Harper sold 17,500 shares of the company's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 over the last 90 days. 11.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CPRX has been the subject of a number of recent research reports. Bank of America reissued a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 11th. Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. HC Wainwright increased their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Finally, Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $32.86.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.